HE4与CA125联合检测用于卵巢癌的诊断

The Combined Detection of HE4 and CA125 in the Diagnosis of Ovarian Cancer

目的探讨人血清附睾蛋白4(HE4)和糖类抗原125(CA125)联合检测在卵巢恶性肿瘤的早期诊断价值。方法选择49例卵巢恶性病变患者(恶性病变组)、68例良性病变患者(良性病变组)及38例体检健康妇女(健康对照组),采用电化学发光免疫法及酶联免疫法测定其血清CA125与HE4水平。结果卵巢癌恶性病变组的CA125与HE4水平均显著高于健康对照组(P<0.01),卵巢良性病变组的CA125和HE4水平与健康对照组相比有统计学意义(P<0.05);CA125与HFA联合检测的灵敏度(87.8%)明显高于单项检测的CA125(77.6%)或HE4(69.4%)。联合检测的阴性预测值(93.3%)明显高于单独检测的CA125(88.3%)和HE4(87.1%)。结论血清CA125与HE4联合检测可提高卵巢恶性肿瘤的诊断的灵敏度和特异性,有利于卵巢癌的早期诊断。

Objective To investigate the value of human epididymis protein 4（HE4） and carbohydrate anti-gen 125（CA125） combined detection in early diagnosis of malignant ovarian tumors .Methods Forty nine cases of ovar-ian malignant lesions（malignant group）,68 cases of patients with benign lesions （Benign lesions group） and 38 cases of physical healthy women （ healthy control group） were selected.Electrochemiluminescence immunoassay and enzyme-linked immunosorbent assay were used to analysis the levels of serum CA 125 and HE4.Results The levels of CA125 and HE4 in ovarian cancer and malignant lesions group were significant higher than that in healthy control group （P〈0. 01）.The levels of CA125 and HE4 in ovarian benign lesion group were statistically significant compared with that in healthy control group（P〈0.05）.The sensitivity of combined detection of CA125 and HE4（87.8%） was significantly higher than that of the single detection of CA125（77.6%） or HE4（69.4%）,HE4 and CA125 assay negative predictive value（93.3%） is significantly higher than separate detection of CA125（88.3%） and HE4（87.1%）.Conclusion Combined detection of serum CA125 and HE4 can improve the sensitivity and specificity in the diagnosis of malignant o-varian tumor.